Rising antibiotic resistance in bacterial pathogens highlights the urgent need to understand the molecular mechanisms by which bacteria cause infections, in order to develop effective precision-based antibiotic-sparing therapies. Gram-negative bacterial pathogens encode over 100 extracellular fibers termed chaperone/usher pathway (CUP) pili able to recognize and colonize different host tissues and habitats, a prerequisite to infection. Each CUP pilus is encoded as part of a gene cluster containing a designated periplasmic chaperone and outer membrane (OM) usher protein that facilitates assembly of tens of hundreds of structural subunits into each final pilus structure. In addition, most CUP pili are tipped by two-domain adhesins comprising: i) an N-terminal domain that recognizes a receptor with stereochemical specificity; and ii) a C-terminal pilin domain. Chaperone- subunit/adhesin complexes are formed through a donor strand complementation (DSC) interaction in which the chaperone donates steric information to promote the folding of the pilin domains and are then delivered to the OM usher which catalyzes subunit-subunit interactions via donor strand exchange (DSE). DSE occurs when an amino-terminal extension (Nte) present on each subunit completes the Ig fold of its neighbor. Pilus biogenesis catalyzed by the OM usher is a remarkably complex process involving the multiple domains of the usher functioning as a nanomachine to assemble pili tipped with an adhesin. With the support from this grant, considerable progress has been made towards elucidating the mechanism of pilus biogenesis, however, this proposal seeks to fill key knowledge gaps: understanding the molecular workings of the usher. To do this, we will elucidate three-dimensional structures of usher intermediates representing critical points in the assembly cascade: i) pilus initiation; and ii) subunit incorporation/(DSE) using X-ray crystallography and single-particle cryo-electron microscopy (Aim 1). We will elucidate the mechanisms by which both two-domain adhesins and specialized single-domain pilins activate ushers in three distinct pilus systems (Aim 2). Understanding the molecular biology of CUP pili has already led to a FimH-based vaccine that was developed to prevent recurrent uropathogenic E. coli (UPEC) urinary tract infections (UTI). This was developed based on understanding that type 1 pili tipped with FimH mediate bladder colonization. The vaccine has completed a Phase 1A/1B study and received FDA allowance for compassionate use based on promising results. In addition, rationally designed inhibitors of FimH function, termed mannosides, have been shown to be highly efficacious in treating and preventing UTI in mouse models, while simultaneously being able to selectively deplete UPEC from the mouse gastrointestinal tract reservoir. Here, small molecules that block usher function will be developed (Aim 3), which would potentially block assembly of multiple CUP pili and work synergistically with other therapeutics. Thus, structural and functional insights will be gained and integrated to develop antibiotic-sparing therapeutics that prevent UPEC colonization by blocking usher and adhesin function.

Public Health Relevance

This proposal seeks to determine the molecular mechanism(s) by which chaperone usher pathway (CUP) pili are assembled and to develop inhibitors of this process. CUP fibers are critical virulence factors encoded in a variety of Gram-negative pathogens and thus, knowledge gained through this work will provide new opportunities for further development of antibiotic-sparing treatment strategies that are sorely needed in this age of increasing antibiotic resistance.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI029549-30
Application #
10022092
Study Section
Bacterial Pathogenesis Study Section (BACP)
Program Officer
Ernst, Nancy L
Project Start
1991-03-01
Project End
2024-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
30
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Washington University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Omattage, Natalie S; Deng, Zengqin; Pinkner, Jerome S et al. (2018) Structural basis for usher activation and intramolecular subunit transfer in P pilus biogenesis in Escherichia coli. Nat Microbiol 3:1362-1368
Spaulding, Caitlin N; Klein, Roger D; Schreiber 4th, Henry L et al. (2018) Precision antimicrobial therapeutics: the path of least resistance? NPJ Biofilms Microbiomes 4:4
Kalas, Vasilios; Pinkner, Jerome S; Hannan, Thomas J et al. (2017) Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions. Sci Adv 3:e1601944
Floyd, Kyle A; Mitchell, Courtney A; Eberly, Allison R et al. (2016) The UbiI (VisC) Aerobic Ubiquinone Synthase Is Required for Expression of Type 1 Pili, Biofilm Formation, and Pathogenesis in Uropathogenic Escherichia coli. J Bacteriol 198:2662-72
O'Brien, Valerie P; Hannan, Thomas J; Nielsen, Hailyn V et al. (2016) Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections. Microbiol Spectr 4:
Spaulding, Caitlin N; Hultgren, Scott J (2016) Adhesive Pili in UTI Pathogenesis and Drug Development. Pathogens 5:
O'Brien, Valerie P; Hannan, Thomas J; Schaeffer, Anthony J et al. (2015) Are you experienced? Understanding bladder innate immunity in the context of recurrent urinary tract infection. Curr Opin Infect Dis 28:97-105
Greene, Sarah E; Hibbing, Michael E; Janetka, James et al. (2015) Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli. MBio 6:e00820
Werneburg, Glenn T; Henderson, Nadine S; Portnoy, Erica B et al. (2015) The pilus usher controls protein interactions via domain masking and is functional as an oligomer. Nat Struct Mol Biol 22:540-6
Dang, Hung The; Chorell, Erik; Uvell, Hanna et al. (2014) Syntheses and biological evaluation of 2-amino-3-acyl-tetrahydrobenzothiophene derivatives; antibacterial agents with antivirulence activity. Org Biomol Chem 12:1942-56

Showing the most recent 10 out of 79 publications